0.63
+0.0453(+7.68%)
Currency In USD
| Previous Close | 0.59 |
| Open | 0.6 |
| Day High | 0.65 |
| Day Low | 0.58 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 8.08M |
| Average Volume | 21.69M |
| Market Cap | 38.4M |
| PE | -0.46 |
| EPS | -1.39 |
| Moving Average 50 Days | 0.56 |
| Moving Average 200 Days | 0.7 |
| Change | 0.05 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.02 as of October 24, 2025 at a share price of $0.635. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $17.06 as of October 24, 2025 at a share price of $0.635.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
GlobeNewswire Inc.
Oct 21, 2025 11:30 AM GMT
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinic
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
GlobeNewswire Inc.
Sep 25, 2025 11:30 AM GMT
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with UnitedHealthcare Insura
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT
GlobeNewswire Inc.
Sep 22, 2025 11:30 AM GMT
Non-dilutive payment is part of $17.6 million award granted for the Company’s leptomeningeal cancer targeted radiotherapeutic development program HOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a